Multiplatform curation in the development of ACMG/AMP specifications for Von Hippel-Lindau (VHL) disease.

PURPOSE: The Clinical Genome Resource (ClinGen) Von Hippel-Lindau (VHL) Variant Curation Expert Panel (VCEP) has created variant classification specifications tailored to the VHL gene, including phenotype-driven and evidence-based criteria, utilizing somatic and germline mutational hotspots, along with functional and in silico data.

METHODS

Using the American College of Medical Genetics and Genomics guidance and the ClinGen Sequence Variant Interpretation recommendations, the VCEP made substantial modifications to 8 evidence codes (PVS1, PS3, PS4, PM1, BS2, BS3, BS4, and BP5), whereas 14 had minor changes, and 6 were not used (PM3, PP2, BP1, PP4, PP5/BP6). The VHL VCEP applied 2 literature sets of over >428 articles in Clinical Interpretations of Variants in Cancer and >8700 structured annotations using Hypothesis.

RESULTS

From 31 pilot variants, 15 remained pathogenic/likely pathogenic, and 9 resolved to benign through the stand-alone benign evidence code, whereas 7 variants with initial uncertain classifications lacking additional evidence, remained uncertain.

CONCLUSION

The versioned VHL VCEP Specifications are publicly available in the ClinGen Criteria Specifications Registry and will enhance the transparency and consistency of variant classifications for this highly sequenced hereditary cancer gene.